Welcome to our dedicated page for ProPhase Labs SEC filings (Ticker: PRPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProPhase Labs, Inc. filings document material events, capital-structure changes, listing status, and operating updates for an OTC-traded life sciences, diagnostics, genomics and consumer health company. Form 8-K disclosures cover the BE-Smart™ esophageal cancer risk stratification test, Crown Medical Collections activity involving legacy COVID-19 testing receivables, shareholder communications, and updates on underlying assets.
The company’s SEC record also includes disclosures on common stock listed for OTC trading under PRPH, a Nasdaq Form 25 delisting notice, a reverse stock split, convertible debt conversions, an equity line stock purchase agreement, related warrant issuance, and unregistered equity sales. Periodic-reporting records include an NT 10-K notice tied to the year-end financial reporting process.
ProPhase Labs, Inc. filed a current report to highlight an investor-focused communication event. On February 2, 2026, the company issued a press release inviting investors to a webinar scheduled for February 3, 2026 at 4:15 p.m. Eastern Time.
The webinar was intended to provide insight into ProPhase’s portfolio of high-growth healthcare assets and included a live question-and-answer session with attendees. The press release containing additional details about the event is furnished as Exhibit 1.1 to the report.
ProPhase Labs, Inc. filed a current report to share that it has issued a new press release about its efforts to recover legacy COVID-19 testing receivables. The update focuses on the Company’s Crown Medical Collections initiative, which is working on amounts owed to its laboratory subsidiaries that are currently in Chapter 11 proceedings. The press release, dated January 26, 2026, is attached as an exhibit to the report, providing more detail on the operational progress of this collection effort.
ProPhase Labs, Inc. filed a current report to inform shareholders that its common stock has been approved for trading and uplisted from the Pink Sheets to the OTCID Market. This change was announced in a press release dated January 22, 2026, which is included as an exhibit.
The move from the Pink Sheets to the OTCID Market reflects a change in the trading venue for the company’s common stock under the symbol PRPH.
ProPhase Labs, Inc. entered into a Stock Purchase Agreement with Generating Alpha Ltd., giving the company the right to draw up to $10,000,000 of equity capital over time at its own election. The agreement creates an equity line facility, meaning ProPhase can choose if and when to sell shares of its common stock to the investor, with no obligation to use the facility.
As a commitment fee for establishing this facility, ProPhase issued 549,105 shares of common stock and a prefunded common stock purchase warrant to acquire up to 240,369 shares, with an exercise price of $0.00 per share on a cashless basis, subject to customary ownership limits. The securities were issued in a private transaction relying on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D.
ProPhase Labs, Inc. is having its common stock removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq has certified that it has complied with its own rules to strike this class of securities from listing and registration, and that the issuer has complied with applicable exchange rules and regulatory requirements for voluntary withdrawal. The notification is signed on behalf of Nasdaq by a hearings advisor, confirming the exchange’s belief that it meets all requirements to file Form 25.
ProPhase Labs, Inc. reported on recent volatility in its common stock and explained several technical factors affecting its capital structure. The company highlighted accelerated conversion and resale of its convertible debt, a 1-for-10 reverse stock split effective December 5, 2025, and its transition from the Nasdaq Capital Market to trading on the OTC market effective January 5, 2026, following a Nasdaq delisting that may reduce liquidity and institutional interest.
More than $3,300,000 of convertible debt principal has been converted out of approximately $3,800,000 originally outstanding, reducing debt and increasing stockholders’ equity, but adding a substantial number of shares to the public market. Management stated that most conversion activity is complete, with less than $500,000 principal remaining, and noted that recent conversions were at a floor conversion price of $0.76 per share. The company emphasized that these mechanics have not changed the intrinsic value of its operating subsidiaries and that it remains focused on stabilizing its capital structure, completing near-term financing initiatives, and advancing its core businesses.
ProPhase Labs, Inc. reported that Board member Warren Hirsch resigned from the Board of Directors effective immediately on January 5, 2026. The company states that Mr. Hirsch’s resignation was not due to any disagreement with ProPhase Labs regarding its operations, policies, or practices, indicating an orderly and non-contentious departure. The Board and the company expressed appreciation for his service and contributions during his tenure.
ProPhase Labs, Inc. is implementing a 1-for-10 reverse stock split of its common stock. Stockholders approved the amendment to the Certificate of Incorporation and the Board of Directors authorized it, with a Certificate of Amendment filed in Delaware on December 2, 2025. The reverse split is intended to increase the trading price of the stock to meet continued Nasdaq listing requirements and becomes effective at 8:00 a.m. Eastern Time on December 22, 2025.
At that time, every 10 shares of common stock will automatically be combined into 1 share. No fractional shares will be issued; instead, any fractional amount will be rounded up so each affected holder receives one whole share. The reverse split applies uniformly, does not change the par value or authorized share count, and is not designed to alter relative ownership percentages aside from rounding. Following the effective date, the company expects to have approximately 5,768,951 shares outstanding, with proportionate adjustments to equity awards, warrants and other convertible securities.
ProPhase Labs, Inc. is implementing a 1-for-10 reverse stock split of its common stock to increase the per-share trading price and meet continued Nasdaq listing requirements. The split, previously approved by stockholders on November 24, 2025 and by the board on November 30, 2025, follows a Certificate of Amendment filed in Delaware on December 2, 2025 and becomes effective at 8:00 a.m. Eastern Time on December 22, 2025.
At the effective time, every 10 shares will combine into 1 share, with fractional positions rounded up so affected holders receive a whole share. The company expects to have approximately 5,768,951 shares of common stock issued and outstanding after the reverse split. The action applies uniformly to all stockholders and does not change the par value, authorized share count, or rights of the common stock, and related equity awards, warrants and other convertible securities will be adjusted proportionately while trading continues on Nasdaq under the PRPH symbol.
ProPhase Labs, Inc. implemented a reverse stock split of its common stock at a ratio of one share for every ten shares outstanding, effective December 2, 2025. The move is intended to increase the per-share trading price to meet continued listing requirements for the Nasdaq Capital Market.
As a result of the reverse split, every ten pre-split shares were automatically combined into one post-split share, with no change to the $0.0005 par value. Fractional share positions were rounded up to the nearest whole share, and no fractional shares were issued. Following the effective date, the company has approximately 5,768,951 shares of common stock issued and outstanding, and the stock continues to trade under the symbol PRPH.